Between debt and discovery: Takeda’s uneasy next phase

Takeda (TYO: 4502) sits in a peculiar place in global pharma. As Japan’s largest drugmaker, it retains a national heritage and corporate culture rooted in Osaka. Yet since the $62 billion Shire acquisition closed in 2019, Takeda has positioned itself as a global heavyweight.

The integration brought scale in rare disease and neuroscience, but also a mountain of debt and questions over whether the gamble would pay off. Now, with leadership set to change in 2026 and late-stage pipeline readouts looming, Takeda stands at a crossroads.